You are here: Home » 2022 » Archives for March 2022

MultiChoice Accelerator Programme Celebrated at World Expo 2020, Dubai

Johannesburg, March 29, 2022 (GLOBE NEWSWIRE) — Team South Africa celebrated their overall success by hosting the last National Day at the World Expo 2020 Dubai. Expo 2020, which started in October 2021, saw almost 200 countries come together to display their offerings, while scouting networking opportunities, drawing investments, and solidifying relationships and future partnerships. The Department of Trade, Industry and Competition (dtic), together with MultiChoice as the official broadcast partner, set out to introduce the diverse economic value that South Africa has to offer.

The six–month participation was closed out with a national ceremony hosted by the Honourable President Cyril Ramaphosa, followed by a high–level panel discussion on the successes of Team SA's participation "" most notably the MultiChoice Accelerator Programme.

In partnership with the dtic, social enterprise agency, C3 (Companies Creating Change), and financial advisory firm, Galelo Africa, the MultiChoice Accelerator Programme initially identified 20 promising South African start–ups for participation in a business incubator. Six finalist companies then had the opportunity to participate in an intense virtual bootcamp and pitch to venture capitalists in the UAE.

"Through Team SA's participation at Expo 2020, we have built lasting relationships, partnerships and networks by taking South Africa to the world. The most tangible success can be seen through our Accelerator Programme where our finalists have gone on to secure more than USD10 million in investment from the UAE," said Imtiaz Patel, MultiChoice Non–Executive Chairman.

Speaking at the Accelerator Programme Roundtable, President Cyril Ramaphosa, addressed the entrepreneurs saying: "You are truly trailblazers, and are flying our flag high here at Dubai Expo 2020. What is most energising about this programme is that you are showing the world that South Africa has a vibrant start–up culture, as well as advanced innovation ecosystems.

"Innovation in science and tech is key to our country's industrialisation, especially in the post–COVID–19 recovery period," the President added.

Team South Africa participated in the Expo under the theme Think South Africa, Think Opportunity.

Attachment


GLOBENEWSWIRE (Distribution ID 8512048)

Conagen’s Grant Award Opens New Markets for Monoclonal Antibodies

Bedford, Mass., March 29, 2022 (GLOBE NEWSWIRE) — The Bill & Melinda Gates Foundation has given a grant to Conagen to support further development of its Conamax(TM) platform for the production of accessible low–cost and high–quality monoclonal antibodies, benefitting developing countries and patients globally.

The high cost of monoclonal antibody (mAb) production makes blockbuster drugs expensive, limiting the markets in which these molecules can be applied and limiting access to large patient populations in developing and industrialized countries. The reason for high production costs is, in part, intrinsic to the use of mammalian cell expression systems for antibody manufacturing.

"The Conamax platform was originally conceived to address this global unmet need, so we are thrilled to have the support of the Bill & Melinda Gates Foundation to help develop affordable antibody therapeutics," said Casey Lippmeier, Ph.D., vice president of innovation at Conagen.

With rapid cell growth, human–compatible glycan structures, and demonstrated world–scale fermentation bioprocesses, the Conamax platform holds several advantages over Chinese Hamster Ovary (CHO) cell lines and other mammalian expression systems, as well as other microbial platforms.

The foundation grant funds the bench–scale development of a proof–of–concept study of a continuous purification process, customized to inputs from Conamax and potentially other microbial host organisms. With large–scale advancements, Conagen envisions that this process will be capable of continuously purifying mAbs from material generated in bioreactors with volumes greater than 250,000 liters.

As a significant advantage, the process will not require expensive binding proteins or other expensive column purification steps. This process will enable economies of scale which are not accessible to CHO or other mammalian–derived cell systems while also providing rapid, high–throughput purification of large amounts of antibody.

"Incumbent antibody manufacturing and purification processes based on Chinese Hamster Ovary (CHO) cell lines have brought tremendous advancements to biopharmaceuticals,” said Lippmeier. “However, CHO cell systems are comparatively low volume, expensive, and do not enable low cost and efficient purification of large amounts of antibodies."

According to McKinsey, in 2019, global sales revenue for all mAb drugs was nearly $163 billion, representing about 70% of the total sales for all biopharmaceutical products, approximately $230 billion. That is about a 50% growth in sales and proportion since 2013, when it was $75 billion.

Continued growth in sales of currently approved mAb products, along with more than 1,200 mAb product candidates currently in development "" many for multiple indications "" will continue to drive the overall sales of all biopharmaceutical products.

"We're unlocking the way to make drugs more affordable and, while doing so, opening additional markets for biologics," said Lippmeier.

###

About Conagen
Conagen is a product–focused synthetic biology R&D company with large–scale manufacturing service capabilities. Our scientists and engineers use the latest synthetic biology tools to develop high–quality, sustainable, nature–based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high–value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

Attachment


GLOBENEWSWIRE (Distribution ID 8511922)

LeddarTech Will Unlock the Value of Raw Data Fusion and Perception at Automotive Tech.AD Berlin (Germany) on April 3-5, 2022

QUEBEC CITY, March 29, 2022 (GLOBE NEWSWIRE) — LeddarTech , a global leader in providing the most flexible, robust and accurate ADAS and AD sensing technology, is pleased to announce its participation at Automotive Tech.AD Berlin at the Titanic Chaussee Hotel Berlin as an exhibitor and keynote speaker.

April 4–5, 2022: LeddarTech's LeddarVision Demonstrator Space (live and virtual)

Join the LeddarTech team for real–world demonstrations of LeddarVision. The only sensor fusion and perception software using raw data fusion that simplifies complex sensor sets eliminates the dependency on hardware and provides customers the flexibility to quickly scale solutions across vehicle models, delivering greater ADAS and AD performance.

Meet the CTO of LeddarTech, Pierre Olivier, a pioneer in sensing with over 30 years of experience presenting at these events during the conference:

  • Sunday, April 3, 2022, 19:45 "" 23:00 CET: Icebreaker Session

Topic: The Road to Full Automation – Progress and Challenges

  • Monday, April 4, 2022, 10:00 "" 10:30 CET: Presentation

Topic: Sensing and Perception Technology "" Solutions That Solve Critical Sensing Challenges

Learn about LeddarVision, a raw–data sensor fusion and perception platform that generates a comprehensive 3D RGBD environmental model with multi–sensor support for camera, radar and LiDAR configurations. This software–centric solution delivers superior perception performance exhibited through path planning, free space detection and enhanced object detection, tracking and classification.

About Automotive Tech.AD Berlin

Tech.AD Europe fuels you with new ideas, connections and inspiration. This event is directed at advanced engineers and automotive experts from OEMs, Tier 1s, automotive suppliers, solution providers and leading research institutes focusing on AI + machine learning, sensor and perception technologies, software architectures and AV platforms, testing and validation, commercial vehicles and early deployment, connectivity and 5G, infrastructures and smart cities, safety and security and more. Join over 500 of the most influential technical autonomous vehicle experts and executives in Berlin and online! Join LeddarTech either in person or digitally by registering today at https://www.autonomous–driving–berlin.com/.

About LeddarTech

Founded in 2007, LeddarTech is a comprehensive end–to–end environmental sensing company that enables customers to solve critical sensing, fusion and perception challenges across the entire value chain. LeddarTech provides cost–effective perception solutions scalable from Level 2+ ADAS to Level 5 full autonomy with LeddarVision, a raw–data sensor fusion and perception platform that generates a comprehensive 3D environmental model from a variety of sensor types and configurations. LeddarTech also supports LiDAR manufacturers and Tier 1–2 automotive suppliers with key technology building blocks such as LeddarSteer digital beam steering and the LiDAR XLRator, a development solution for automotive–grade solid–state LiDARs based on the LeddarEngine and core components from global semiconductor partners. The company is responsible for several innovations in cutting–edge automotive and mobility remote–sensing applications, with over 100 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook and YouTube.

Contact:
Daniel Aitken, Vice–President, Global Marketing, Communications and Investor Relations, LeddarTech Inc.
Tel.: + 1–418–653–9000 ext. 232
daniel.aitken@leddartech.com

Investor Relations contact : InvestorRelations@leddartech.com
https://investors.leddartech.com/

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, LeddarEcho, VAYADrive, VayaVision, XLRator and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.


GLOBENEWSWIRE (Distribution ID 8511531)

Synchronoss Personal Cloud Enables Kitamura’s PicStorage Service

BRIDGEWATER, N.J., March 28, 2022 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. ("Synchronoss" or the "Company") (Nasdaq: SNCR), a global leader and innovator in cloud, messaging and digital products and platforms, today announced that Kitamura, the leading multimedia retailer in Japan, has launched a white–label version of the Synchronoss Personal Cloud under the name PicStorage.

Kitamura is one of Japan's leading retailers offering image–related services and products, including cameras, photo printing, video dubbing, photo studio, photo books and more. The retailer has over 1,000 retail locations across the country with over 20 million paying visitors each year and approximately 10 million consumers registered in its online services. Through this integration, Kitamura will be able to provide seamless online and retail experiences with the new PicStorage personal cloud offering.

"In addition to our carrier and service provider partners, Synchronoss is exploring new applications for our cloud platform," said Yosuke Morioka, General Manager, Synchronoss Japan. "Our collaboration with Kitamura and their launch of PicStorage is just one example of how the Synchronoss Personal Cloud can be leveraged as a value–add service across multiple industries and verticals. "

Kitamura will offer PicStorage as a subscription–based service. It will include a branded app and access to an online portal to store, manage, and share digital content.

"The launch of PicStorage is a perfect extension of our product and services portfolio," said Hajime Yanagisawa, Chief Digital Officer & Managing Executive Officer, Kitamura. "Now millions of our customers will be able to safeguard their digital content in the cloud and share them with friends and family. PicStorage allows the customer to experience new ways to organize and enjoy their photos and memories. Kitamura will continue to expand this service with photo related services that will enhance the customer experience."

In addition to Kitamura, Synchronoss has customers in the US, Europe, and Asia, including Verizon, AT&T, Tracfone, Assurant, Allstate Protection Plans, Telkomsel, BT, Proximus and SFR.

About Kitamura
Kitamura is a leading company of photographic and video–related products and services in Japan. The company owns Japan's largest in–house laboratories (photo and video processing factories) and delivers its services and products via more than 1,000 retail stores nationwide and online. It is the company's mission to provide services to shape customer memories not only at that moment but also for decades to come, restore photos, and revive precious memories.

About Synchronoss

Synchronoss Technologies (Nasdaq: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways. The company's collection of products helps streamline networks, simplify onboarding, and engage subscribers to unleash new revenue streams, reduce costs and increase speed to market. Hundreds of millions of subscribers trust Synchronoss products to stay in sync with the people, services, and content they love. That's why more than 1,500 talented Synchronoss employees worldwide strive each day to reimagine a world in sync. Learn more at www.synchronoss.com.

Media Relations Contact:
Domenick Cilea
Springboard
dcilea@springboardpr.com

Investor Relations Contact:
Matt Glover / Tom Colton
Gateway Group, Inc.
SNCR@gatewayir.com


GLOBENEWSWIRE (Distribution ID 8511313)

AKBA INVESTOR NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AKBA

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the "Class Period"), of the important May 13, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Akebia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Akebia class action, go to https://rosenlegal.com/submit–form/?case_id=4028 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) vadadustat was not as safe in treating NDD–CKD patients with anemia as defendants had represented; (2) as a result, defendants overstated the PRO2TECT Program's clinical prospects; (3) accordingly, defendants also overstated vadadustat's overall commercial and regulatory prospects; and (4) as a result, Akebia's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Akebia class action, go to https://rosenlegal.com/submit–form/?case_id=4028 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8509737)

INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Breaches of Fiduciary Duties and Negligence by The Vanguard Group, Inc., Vanguard Chester Funds, and Certain Officers and Trustees – VTWNX, VTTVX, VTHRX, VTTHX, VFORX, VTIVX, VFIFX

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties and negligence by The Vanguard Group, Inc., Vanguard Chester Funds, and certain officers and trustees (MUTF: VTWNX, VTTVX, VTHRX, VTTHX, VFORX, VTIVX, VFIFX) resulting from allegations that management may have issued materially misleading information to the investing public.

If you invested in Vanguard's retail funds, held these funds in taxable accounts, and received 2021 capital gains distributions, please visit the firm's website at https://rosenlegal.com/submit–form/?case_id=4732 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866–767–3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm's attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8509937)

ROSEN, NATIONAL TRIAL LAWYERS, Encourages TaskUs, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action – TASK

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of TaskUs, Inc. (NASDAQ: TASK) between June 11, 2021 and January 19, 2022, inclusive (the "Class Period"), of the important April 25, 2022 lead plaintiff deadline.

SO WHAT: If you purchased TaskUs securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the TaskUs class action, go to https://rosenlegal.com/submit–form/?case_id=3647 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 25, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) TaskUs was experiencing severe financial strain and business challenges, particularly with its most important customer Facebook; (2) the Content Security market was smaller than defendants represented and defendants' representations were based on outdated market data; (3) TaskUs improperly recognized revenue from certain key contracts; (4) defendants overstated the size of TaskUs' workforce as well as employee retention rates, and understated attrition rates; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the TaskUs class action, go to https://rosenlegal.com/submit–form/?case_id=3647 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8509919)

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages TAL Education Group Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action – TAL

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of TAL Education Group (NYSE: TAL) between April 26, 2018 and July 22, 2021, inclusive (the "Class Period"), of the important April 5, 2022 lead plaintiff deadline.

SO WHAT: If you purchased TAL Education securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the TAL Education class action, go to https://rosenlegal.com/submit–form/?case_id=3137 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 5, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) TAL Education's revenue and operational growth was the result of deceptive marketing tactics and illicit business practices that flouted Chinese laws, regulations, and policies, and exposed TAL Education to an extreme risk that more draconian measures would be imposed on TAL Education; (2) TAL Education had engaged in misleading and fraudulent advertising practices, including the provision of false and misleading discount information designed to obfuscate the true cost of TAL Education's programs to its customers, the creation of fake customer reviews designed to fraudulently lure new customers to TAL Education programs, the misrepresentation of teacher qualifications and course qualities, and the marketing of rigged promotional events; (3) TAL Education had defied Chinese policies designed to alleviate the burden imposed by tutoring services on students and their families, including by imposing hefty advances and recurring debt payments on course enrollees, by offering courses designed to give affluent students unfair advantages, by holding courses outside of allowable tutoring hours, and by linking for–profit courses to government–mandated schooling; (4) as a result, TAL Education was subject to an extreme undisclosed risk of adverse enforcement actions, regulatory fines, and penalties, and the imposition of new rules and regulations adverse to TAL Education's business and financial interests; and (5) consequently, TAL Education's historical growth was not sustainable or the result of legitimate business tactics as represented, and defendants' positive statements about TAL Education's business, operations, and prospects were materially false and misleading and lacked a reasonable factual basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the TAL Education class action, go to https://rosenlegal.com/submit–form/?case_id=3137 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8509903)

Nyxoah Reports Full Year 2021 Operating and Financial Results

REGULATED INFORMATION

Nyxoah Reports Full Year 2021 Operating and Financial Results

Mont–Saint–Guibert, Belgium "" March 24, 2022, 9:30pm CET / 4:30pm ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the full year ending December 31, 2021.

Full Year 2021 Operational and Financial Highlights

  • Generated revenue of 852,000 from the commercialization of Genio in Europe, mainly in Germany; gross margin was 64.4%
  • Achieved strong commercial progress in Germany after obtaining a DRG code for the Genio system
  • Obtained DRG coding in Switzerland and hospital reimbursement in Spain; awaiting reimbursement decisions in other key European markets
  • Reported positive data from the BETTER SLEEP clinical trial, which achieved its primary safety and performance endpoints, with statistically significant reduction in baseline AHI scores for the overall study and the complete concentric collapse (CCC) and non–CCC patient cohorts; per the Sher criteria, after 6 months, achieved responder rates of 64% for the entire population (CCC and non–CCC), 60% for the CCC cohort, and 67% for the non–CCC cohort
  • Received expanded CE mark indication to treat CCC patients, thus increasing the total addressable market by at least 30% and enabling patients not to have to undergo a Drug–Induced Sleep Endoscopy (DISE) procedure prior to implantation
  • Granted U.S. FDA Breakthrough Device Designation for the treatment of adult patients with moderate–to–severe OSA and CCC; awaiting IDE approval to commence a trial for CCC patients in the U.S. in late 2022
  • Advanced patient enrollment in the DREAM U.S. IDE study, with implants expected to be completed in the second quarter of 2022
  • Raised $97.8 million in a Nasdaq initial public offering in July, successfully completing Nyxoah's second IPO after previously raising 84.8 million in the September 2020 Euronext Brussels IPO
  • Entered exclusive licensing agreement with Vanderbilt University (US) to develop next generation neurostimulation technologies, specifically a novel stimulator focused on the Ansa Cervicalis nerve, which could further expand the eligible to treat OSA patient population.

"2021 was a very strong year for Nyxoah. I am proud of the team maintaining their focus on execution while operating in a challenging market environment. We reached numerous milestones in 2021 and feel we are well positioned to further build on this momentum in 2022," commented Olivier Taelman, Nyxoah's Chief Executive Officer. "Through the BETTER SLEEP study results, we are now able to offer an effective solution for CCC patients with an expanded CE mark indication in Europe, and we are working hard to initiate a CCC–focused IDE trial in the US. Particularly encouraging are the strong responder rates in all patient cohorts, further increasing our confidence in positive outcomes from the ongoing DREAM study."

"We have also been happy with our commercial progress in Europe, focusing on Germany, where we obtained a dedicated DRG code." continued Mr. Taelman. "We already had 12 active implant sites in December 2021 and continue to expand rapidly. In addition, we have secured a DRG code in Switzerland and hospital reimbursement in Spain while we await final reimbursement decisions in the Netherlands and Belgium. Our commercial strategy is based on a deep understanding of the patient journey, building strong relationships with implanting surgeons and further strengthening their relationships with referring sleep physicians, in combination with digital marketing programs."

Mr. Taelman continued, "We secured CE mark MR conditional labeling for Genio , enabling all implanted patients to safely undergo 1.5T and 3T MRI diagnostics scans. Genio is now the only HGNS device with an MRI compatibility label for full–body and 3T. This illustrates our patient–centric strategy, and you can soon expect to hear more on the progress made by our R&D team. Short term, we expect to launch the next generation Genio 2.1, which includes a patient–centric smartphone app and will incorporate a position sensor to adjust stimulation levels based on sleeping position. Looking further into the future, we are proud of our collaboration with Vanderbilt University and Dr. Kent that should result in novel treatment options for OSA patients, starting with Ansa Cervicalis stimulation."

"With our second successful IPO in the span of 10 months last July, we have a strong balance sheet that provides ample liquidity to complete the DREAM study, conduct our U.S. CCC IDE study, invest in pre–commercial activities in the U.S., and remain committed to our important R&D priorities. We are extremely excited about where we are today as a company, and we look forward to providing further updates as the year progresses," concluded Mr. Taelman.

Full Year 2021 Results

CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (in thousands)

For the year ended December 31
2021 2020
Revenue 852 69
Cost of goods sold (303) (30)
Gross profit 549 39
General and administrative expenses (11 113) (7 522)
Research and development expenses (2 353) (473)
Clinical expenses (2 706) (1 053)
Manufacturing expenses (4 760) (460)
Quality assurance and regulatory expenses (1 463) (227)
Patents fees & Related (1 062) (123)
Therapy development expenses (3 599) (1 864)
Other operating income / (expenses) 265 459
Operating loss for the period (26 242) (11 224)
Financial income 3 675 62
Financial expense (2 072) (990)
Loss for the period before taxes (24 639) (12 152)
Income taxes (2 980) (93)
Loss for the period (27 619) (12 245)
Loss attributable to equity holders (27 619) (12 245)
Other comprehensive income/(loss)
Items that may not be subsequently reclassified to profit or loss (net of tax)
Remeasurements of post–employment benefit obligations, net of tax (68) '
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences 121 (58)
Total other comprehensive income/(loss) 53 (58)
Total comprehensive loss for the year, net of tax (27 566) (12 303)
Loss attributable to equity holders (27 566) (12 303)
Basic loss per share (in EUR) (1.161) (0.677)
Diluted loss per share (in EUR) (1.161) (0.677)

CONSOLIDATED BALANCE SHEETS (in thousands)

As at December 31
2021 2020
ASSETS
Non–current assets
Property, plant and equipment 2 020 713
Intangible assets 25 322 15 853
Right of use assets 3 218 3 283
Deferred tax asset 46 32
Other long–term receivables 164 91
30 770 19 972
Current assets
Inventory 346 55
Trade receivables 226 '
Other receivables 2 286 1 644
Other current assets 1 693 109
Cash and cash equivalents 135 509 92 300
140 060 94 108
Total assets 170 830 114 080
EQUITY AND LIABILITIES
Capital and reserves
Capital 4 427 3 796
Share premium 228 033 150 936
Share based payment reserve 3 127 2 650
Other comprehensive income 202 149
Retained loss (87 167) (60 341)
Total equity attributable to shareholders 148 622 97 190
LIABILITIES
Non–current liabilities
Financial debt 7 802 7 607
Lease liability 2 737 2 844
Pension liability 80 37
Provisions 12 '
Deferred tax liability 5 '
10 636 10 488
Current liabilities
Financial debt 554 616
Lease liability 582 473
Trade payables 3 995 1 190
Current tax liability 2 808 '
Other payables 3 633 4 123
11 572 6 402
Total liabilities 22 208 16 890
Total equity and liabilities 170 830 114 080

Revenue

Revenue was 852,000 for the twelve months ending December 31, 2021, compared to 69,000 for the twelve months ending December 31, 2020. The increase in revenue was attributable to the Company's commercialization of the Genio system, primarily in Germany. Revenue for the second half of 2021 was 497,000, a 40.0% increase versus the first half of the year despite COVID–related headwinds during the fourth quarter.

Cost of Goods Sold

Cost of goods sold was 303,000 for the twelve months ending December 31, 2021, representing a gross profit of 549,000, or gross margin of 64.4%. This compares to total costs of goods sold of 30,000 in the 2020, for a gross profit of 39,000, or gross margin of 56.5%.

General and Administrative Expenses

General and administrative expenses rose to 11.1 million for the full year ending December 31, 2021, from 7.5 million in the prior year. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah's corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of U.S. commercial launch.

Research and Development Expenses

Research and Development expenses were 2.4 million for the twelve months ending December 31, 2021, a substantial increase over the 0.5 million for the prior year, reflecting the ongoing research and development activities, most notably the development of next generation versions of the Genio system. As of January 2021, the Company started to amortize its intangible assets, which explains the significant increase in depreciation expenses for the twelve months ending December 31, 2021, compared to the twelve months ending December 31, 2020.

Clinical Expenses

Clinical expenses increased to 2.7 million for the twelve months ending December 31, 2021, from 1.1 million for the twelve months ending December 31, 2020. Total clinical expenses were 9.5 million, of which 6.8 million was capitalized, reflecting an increase in staff and consulting to support the completion of the BETTER SLEEP trial implantations, continuous recruitment for the EliSA trial, and the ongoing DREAM IDE trial in the United States.

Manufacturing Expenses

Manufacturing expenses increased to 4.8 million for the twelve months ending December 31, 2021, from 0.5 million for the twelve months ending December 30, 2020, due mainly to increased demand for our Genio system for both commercial and non–commercial purposes.

Quality Assurance and Regulatory Expenses

Quality assurance and regulatory expenses of 1.5 million for the year ending December 31, 2021, were up significantly from 0.2 million for the year ending December 31, 2020, to support the scale–up of operations.

Patent Fees & Related Expenses

Patents fees and related expenses increased from 0.1 million for the twelve months ending December 31, 2020, to 1.1 million for the twelve months ending December 31, 2021, due to expenses related to the exclusive licensing agreement with Vanderbilt University.

Therapy Development Expenses

Therapy development expenses were 3.6 million for the twelve months ending December 31, 2021, versus 1.9 million for the twelve months ending December 31, 2020. The increase in expenses was mainly driven by the scale–up of commercial operations in Europe.

Operating Loss

The Company realized a net loss of 27.6 million for the full year ending December 31, 2021, compared to a net loss of 12.2 million for the full year ending December 31, 2020, due to increases of activities in all departments.

Cash Position

Cash and cash equivalents totaled 135.5 million on December 31, 2021, as compared to 92.3 million on December 31, 2020. The increase was due primarily to total gross proceeds of $97.8 million generated from the July 2021 IPO.

Net cash used in operations was 25.3 million for the twelve months ending December 31, 2021, compared to 6.9 million for the twelve months ending December 31, 2020. The increase was primarily due to an increase in net loss for the period that was mainly attributable to increased general and administrative expenses, research and development expenses, manufacturing expenses and therapy development expenses, which were offset by a positive variation in the working capital of 1.1 million.

Net cash used in investing activities was 11.8 million for the twelve months ending December 31, 2021, compared 10.7 million for the twelve months ending December 31, 2020.

Net cash generated in financing activities for the twelve months ending December 31, 2021, was 76.5 compared to 104.0 million of net cash provided by financing activities during the twelve months ending December 31, 2020.

Outlook for 2022

The Company's business, operational, and clinical outlook for 2022 include the following expected milestones and goals:

  • Completing DREAM trial implants in the second quarter of 2022
  • Continuing commercial execution in Germany
  • Commencing a U.S. IDE study for CCC patients in the fourth quarter of 2022

Full–year report 2021
Nyxoah's financial report for the full year 2021, including details of the audited consolidated results, are available on the investor page of Nyxoah's website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation
Nyxoah will conduct a conference call to open to the public tomorrow, March 25, 2022, at 1:00 p.m. CET / 8:00 a.m. ET, which will also be webcasted. To participate in the conference call, please dial one of the following numbers:

Conference ID: 3688760

USA: (844) 260–3718
Belgium: 0800 73264
International: (929) 517–0938

A question–and–answer session will follow the presentation of the results. To access the live webcast, go to https://investors.nyxoah.com/events. The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward–looking statements
Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio system; the utility of clinical data in potentially obtaining FDA approval of the Genio system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20–F for the year ended December 31, 2021, to be filed with the Securities and Exchange Commission ("SEC") on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Attachment


GLOBENEWSWIRE (Distribution ID 1000612874)

FXCM February Single Share & Stock Baskets Report

JOHANNESBURG, South Africa, March 24, 2022 (GLOBE NEWSWIRE) — FXCM Group, LLC ("FXCM Group' or "FXCM'), the leading international provider of online foreign exchange trading, CFD trading, cryptocurrencies and related services, is today releasing its data of most popular instruments for the month of February in its Single Share CFD and proprietary Stock Basket product lines.

FXCM offers fractional single share trading with no commission fees* on leading companies from the US, UK, France, Germany, Hong Kong and Australia. FXCM's stock basket products combine the shares of multiple companies from one sector into a single tradeable instrument. The company currently boasts a portfolio of 16 stock baskets. The list of companies and weightings is available on FXCM's stock basket website (https://www.fxcm.com/za/stock–baskets/).

The top of the most traded stocks in February saw little change, but the bottom part of the list contains some bolters. EV company Rivian's continual steep decline caught the attention of FXCM traders as they try to catch some of the action of a company that only a few months ago was trading above $170 but has declined over $100 since December. Last month also saw the return of Google and Pfizer to the top ten.

On the stock basket side, Crypto Stocks continues its steady rise up the ranks since its recent product launch, largely at the expense of the Chinese–focused baskets, which have declined to their lowest positions since inception. But it was the drastic rise of pandemic impacted baskets WFH and Travel that catches the eye, as the global restriction from the Omicron variant diminishes and traders try to ride the wave of the potential impact on the respective baskets.

Volume
Rank		 Monthly
Rank Change		 Company Symbol
1 – Tesla Inc TSLA.us
2 '3 Facebook (Meta Platforms Inc) FB.us
3 "1 Amazon.com Inc AMZN.us
4 "1 Alibaba Group Holding Ltd ADR BABA.us
5 '5 NVIDIA Corporation NVDA.us
6 "2 Alibaba Group (HK) BABA.hk
7 "1 Apple Inc AAPL.us
8 '27 Rivian Automotive Inc RIVN.us
9 '10 Alphabet Inc (Google) GOOG.us
10 '17 Pfizer Inc PFE.us

Volume
Rank		 Monthly
Rank Change		 Sector Symbol
1 – Big US Tech FAANG
2 '9 Travel TRAVEL
3 '4 Cryptocurrency Stocks CRYPTOSTOCK
4 "2 Airlines AIRLINES
5 '10 Work From Home WFH
6 "3 China Tech CHN.TECH
7 "3 China Ecommerce CHN.ECOMM
8 '1 Big China Tech (HKD Basket) ATMX
9 "4 ESports & Gaming ESPORTS
10 "4 Cannabis CANNABIS

Past Performance and popularity is not an indicator of future results.
Rank is derived from FXCM Client Volume

*FXCM can be compensated in several ways, which includes but are not limited to adding a mark–up to the spreads it receives from its liquidity providers, adding a mark–up to rollover, etc. Commission–based pricing is applicable to Active Trader account types.

ENDS

About FXCM:

FXCM is a leading provider of online foreign exchange (FX) trading, CFD trading, and related services. Founded in 1999, the company's mission is to provide global traders with access to the world's largest and most liquid market by offering innovative trading tools, hiring excellent trading educators, meeting strict financial standards and striving for the best online trading experience in the market. Clients have the advantage of mobile trading, one–click order execution and trading from real–time charts. In addition, FXCM offers educational courses on FX trading and provides trading tools, proprietary data and premium resources. FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime. FXCM is a Leucadia Company.

Forex Capital Markets Limited: FCA registration number 217689 (www.fxcm.com/uk)

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

63% of retail investor accounts lose money when trading CFDs with this provider.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM EU LTD: CySEC license number 392/20 (www.fxcm.com/eu)

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

74% of retail investor accounts lose money when trading CFDs.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM Australia Pty. Limited: AFSL 309763. Losses can exceed your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved. If you decide to trade products offered by FXCM AU, you must read and understand the Financial Services Guide, Product Disclosure Statement, Target Market Determination and Terms of Business on www.fxcm.com/au.

FXCM South Africa (PTY) Ltd: FSP No 46534 (www.fxcm.com/za). Our service includes products that are traded on margin and carry a risk of losses in excess of your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved.

FXCM Markets Limited: Losses can exceed deposited funds. (www.fxcm.com/markets).

Media contact:
Chatsworth Communications
+44 (0) 20 7440 9780
fxcm@chatsworthcommunications.com


GLOBENEWSWIRE (Distribution ID 8509657)